Welcome to Peplin
We are a Phase III specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products. We are currently developing PEP005 (ingenol mebutate), or PEP005, which is the first in a new class of compounds and which is derived from Euphorbia peplus, or E. peplus, a rapidly growing, readily-available plant, commonly referred to as petty spurge or radium weed. The sap of E. peplus has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, such as skin cancer and pre-cancerous skin lesions. Peplin has extensive international patent coverage over its technologies.
Company Highlights
Phase IIb Positive Results
Peplin announced positive results for PEP005 (ingenol mebutate) Gel in its Phase IIb actinic (solar) keratosis (AK) dose ranging clinical trial (PEP005-015) for the treatment of AK lesions on head locations. The trial met the primary efficacy endpoint with statistically significant complete clearance rate of AK lesions vs. vehicle. In addition, there was a reduction in overall lesion count in all active treatment groups. The side effects were well-tolerated local skin responses which dissolved rapidly at all concentrations and durations.
REGION-I Trial Enrolment Complete
Peplin has completed enrolment of its US and Australian 250 patient Phase III clinical trial to confirm the efficacy and safety of PEP005 ingenol mebutate) Gel for the treatment of actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, when applied to non-head locations, which include the trunk and extremities.
$24m financing and Neosil acquisition complete
Peplin has closed its acquisition of Neosil, providing ~$6m in cash plus early stage dermatology assets, and raised $24m in financing lead by new investor GBS and including existing investors MPM, NEA, and Orbis. This provides a June 30, 2008 pro-forma balance = $56m, sufficient amount to fund Phase III development.
Sign up to receive email alerts regarding Peplin news and financials here
Contact us
Medical information
Telephone: +1-800-881-5754
Email: peplin@medcomsol.com
Clinical trial information
Please refer to www.clinicaltrials.gov for trial information
Corporate information
Email: info@peplin.com
USA
6475 Christie Avenue
Suite 300
Emeryville, California 94608
Telephone: +1-510 653 9700
Facsimile: +1-510 653 9704
AUSTRALIA
Level 2, Brisbane Portal
1 Breakfast Creek Road
Newstead
Brisbane, Queensland 4006
Telephone: +61-7-3250 1200
Facsimile: +61-7-3250 1299